...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >STANDARDIZATION, FORMULATION DEVELOPMENT AND CHARACTERIZATION OF ANTIULCER DRUG: MUKTA BHASMA
【24h】

STANDARDIZATION, FORMULATION DEVELOPMENT AND CHARACTERIZATION OF ANTIULCER DRUG: MUKTA BHASMA

机译:抗软体药的标准化,配方开发和表征:Mukta Bhasma

获取原文

摘要

Ayurveda is the holistic approach towards life, health, disease management through medicinal herbs minerals, diet and lifestyle leads to the great need for standardization of herbal medicine to maintain its safety and efficacy. Mukta bhasma is used in the treatment of bone metabolic disorders associated with calcium deficiency. It was prepared by Shodhana, Marana and Sharava samputa and the Standardization of bhasma are very necessary to confirm its identity and to determine its quality and purity. An attempt has been made to summarize the ancient and the advanced methods available for the standardization of bhasma. The dosage uniformity and patient compliance can be increased and adulteration can be decreased in ayurvedic powders by formulating them into tablets. The aim of the present work is to develop and evaluate Mukta Bhasma tablets using starch and acacia as a binder. The granules were prepared by the wet granulation method. The prepared tablets were evaluated for different parameters, acute toxicity of Mukta bhasma was conducted on albino rats. Mukta bhasma was administered orally in albino rats of single maximum limit dose 2000 mg/kg and general behavioral observation along with any mortality was recorded. Acute toxicity study shows that there is no adverse effect of bhasma on albino rats even at a single dose of 2000 mg/kg body weight that reveals that Mukta bhasma is safe in albino rats. The results suggest that this ayurvedic preparation cannot show any signs and symptoms of toxicity.
机译:Ayurveda是通过药草矿物质,饮食和生活方式来实现生命,健康,疾病管理的整体方法,导致草药标准化的巨大需求保持其安全性和功效。 Mukta Bhasma用于治疗与缺钙相关的骨代谢障碍。它是由Shodhana,马拉娜和亚马什邦的制作,并且Bhasma的标准化非常有必要确认其身份并确定其质量和纯度。已经尝试总结了古老和高级方法可用于Bhasma标准化。可以增加剂量均匀性和患者顺应性,并且通过将它们配制成片剂,可以在阿育吠虫粉末中降低掺杂剂。本工作的目的是使用淀粉和金合欢作为粘合剂进行开发和评估Mukta Bhasma片剂。通过湿造粒方法制备颗粒。评估制备的片剂对不同的参数,在白化大鼠进行Mukta Bhasma的急性毒性。 Mukta Bhasma在单一最大限制剂量2000mg / kg的白化大鼠中口服给药,并记录了一般行为观察以及任何死亡率。急性毒性研究表明,即使在2000毫克/千克体重的单剂量,均匀的抗菌大鼠对白化大鼠的不良反应,揭示了Mukta Bhasma在白化大鼠中是安全的。结果表明,这种阿育吠陀制剂不能显示任何毒性的迹象和症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号